Business
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
Toronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc.  ...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced FinancingToronto, Ontario--(Newsfile Corp. - December 12, 2025) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) (\"Theralase®\" or the \"Company\"), a clinical stage pharmaceutical company pioneering light, radiation, sound and drug-activated therapeutics for the treatment of cancer, bacteria and viruses, has commenced a non-brokered private placement of units of the Company (\"Units\") to raise up to $CAN 2,000,000 (\"Offering\").In the Offering, each Unit is priced at $CAN 0.17 and consists of one common share of the Company (\"Common Share\") and one Common Share purchase warrant (\"Warrant\"). Each Warrant will entitle the holder thereof to purchase one Common Share of the Company (\"Warrant Share\") for a period of 60 months following the Closing Date (as defined herein) of the Offering at an exercise price of $CAN 0.21 per Warrant Share.The Company plans to use the proceeds of the Offering to further the Phase II Non-Muscle Invasive Bladder Cancer (\"NMIBC\") clinical study currently underway and for working capital needs.All securities issued under the Offering will be subject to a four months and one day hold period from the Closing Date under applicable Canadian and US securities laws.The Offering is scheduled to close on or about the week of December 15, 2025 and is subject to the receipt of all necessary approvals, including the approval of the TSXV (\"Closing Date\").The Offering is being made to accredited investor subscribers resident in each of the Provinces of Canada, pursuant to applicable private placement exemptions, in the United States or to, or for the account of, U.S. persons, on a private placement basis pursuant to an exemption from the registration requirements in Rule 144A or Regulation D of the United States Securities Act of 1933, as amended or other available U.S. registration exemptions and offshore jurisdictions pursuant to relevant prospectus or registration exemptions in accordance with applicable laws.The Company agrees to pay a finder's fee to eligible finders for subscribers, introduced by such finder, in connection with the non-brokered private placement, as follows: i) a cash commission equal to 7% of the gross proceeds and ii) non-transferable finder warrants exercisa...